ARS Pharmaceuticals Earnings Reports

In Q2 2025, ARS Pharmaceuticals generated $15.7M in total revenue, largely from neffy sales in the U.S. and milestone revenue in Germany. Despite the top-line growth, the company posted a net loss of $44.9M due to continued R&D and heavy SG&A spending tied to product promotion.

In Q4 2024, ARS Pharmaceuticals generated total revenue of $86,600,000, which included $6,700,000 in net product revenue from neffy sales in the U.S. and $73,500,000 from collaboration agreements. The company reported net income of $49,900,000 and diluted earnings per share of $0.48. Operating expenses remained controlled, with a focus on commercialization efforts for neffy.

ARS Pharmaceuticals reported a net loss of $19.1 million for Q3 2024. Total revenue was $2.1 million, including $0.6 million in net product revenue from Neffy sales and $1.5 million in collaboration revenue. The company's cash position was strong with $349.6 million on a pro forma basis, adjusted for the $145 million upfront payment from ALK-Abelló.

ARS Pharmaceuticals reported a net loss of $12.5 million for the second quarter of 2024. The company's cash, cash equivalents, and short-term investments were $218.7 million as of June 30, 2024, expected to fund operations for at least three years. The New Drug Application (NDA) for neffy is under review by the FDA, with a PDUFA date in early October 2024.

ARS Pharmaceuticals reported a net loss of $10.3 million for Q1 2024, compared to a net loss of $15.0 million for Q1 2023. The company's cash and securities totaled $223.6 million as of March 31, 2024, which is expected to fund operations for at least three years. The company anticipates potential U.S. launch of neffy in the second half of 2024.

ARS Pharmaceuticals reported its Q4 and full year 2023 financial results, highlighting the submission of response to the FDA's CRL for neffy in early Q2 2024 and successful completion of neffy repeat dose nasal allergen challenge study. The company ended the quarter with $228.4 million in cash, cash equivalents and short-term investments.